Medpace Holdings, Inc. (MEDP) Operating Cash Flow CAGR:27.01%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Medpace Holdings, Inc.'s Operating Cash Flow CAGR averages 20.55% over 3 years and 22.61% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash Medpace Holdings, Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
MEDP Operating Cash Flow CAGR Chart
Medpace Holdings, Inc. (MEDP)
MEDP Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
MEDP Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $608.82M | $713.22M | +$104.41M | +17.15% | +17.15% |
| 2024 | $433.37M | $608.82M | +$175.44M | +40.48% | +40.48% |
| 2023 | $388.05M | $433.37M | +$45.32M | +11.68% | +11.68% |
| 2022 | $263.33M | $388.05M | +$124.72M | +47.36% | +47.36% |
| 2021 | $258.68M | $263.33M | +$4.65M | +1.80% | +1.80% |
| 2020 | $201.87M | $258.68M | +$56.81M | +28.14% | +28.14% |
| 2019 | $156.58M | $201.87M | +$45.28M | +28.92% | +28.92% |
| 2018 | $97.39M | $156.58M | +$59.20M | +60.79% | +60.79% |
| 2017 | $91.73M | $97.39M | +$5.65M | +6.16% | +6.16% |
| 2016 | $85.87M | $91.73M | +$5.86M | +6.83% | +6.83% |
| 2015 | $75.20M | $85.87M | +$10.67M | +14.19% | +14.19% |
| 2014 | $98.14M | $75.20M | $-22.94M | -23.37% | -23.37% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $151.79M | -21.2% | +20.6% |
| Q4 2025 | $192.65M | -21.8% | +1.0% |
| Q3 2025 | $246.21M | +65.8% | +65.2% |
| Q2 2025 | $148.53M | +18.0% | +27.6% |
| Q1 2025 | $125.84M | -34.0% | -17.6% |
| Q4 2024 | $190.67M | +27.9% | +21.9% |
| Q3 2024 | $149.07M | +28.1% | +30.3% |
| Q2 2024 | $116.40M | -23.8% | +41.1% |
| Q1 2024 | $152.68M | -2.4% | +90.7% |
| Q4 2023 | $156.40M | +36.7% | +14.4% |
| Q3 2023 | $114.39M | +38.6% | +5.4% |
| Q2 2023 | $82.52M | +3.0% | -14.6% |
| Q1 2023 | $80.08M | -41.4% | +73.1% |
| Q4 2022 | $136.68M | +26.0% | +92.8% |
| Q3 2022 | $108.49M | +12.3% | +49.9% |
| Q2 2022 | $96.62M | +108.9% | +53.9% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle